Morgan Stanley cuts Compass Pathways stock price target on TRD progress

Compass Pathways reported highly statistically significant results from its second Phase 3 trial for COMP360 and is targeting an NDA submission in Q4 2026 with 26-week Part B data from COMP006 expected in early Q3 2026. The company raised roughly $200M via warrant exercises and priced a 17.5M ADS offering at $8.00 per ADS ($150M), expected to close ~Feb 20, 2026. Morgan Stanley trimmed its price target to $16 from $18 while keeping an Overweight rating, and RBC raised its PT to $22 from $21 (Outperform). Shares trade at $5.25 (down ~12% over the past week, up ~72% over the past year).

Analysis

The principal near-term winner from Compass Pathways' trajectory is the company itself and any upstream CDMOs that can secure GMP psilocybin capacity quickly; securing CMOs now buys optionality for a rapid commercial ramp but transfers fixed-cost and execution risk onto the balance sheet. Competitors in the broader psychedelic/rapid-acting depression space are likely to face investor reallocation flows—capital will concentrate around programs with clear regulatory paths and near-term registrational datasets, increasing financing costs for smaller peers and compressing their optionality.

Key reversal risks are concentrated and time-phased: near-term dilution and manufacturing mis-steps can compress equity value in weeks-to-months, while medium-term reversals hinge on durability/safety signals from the pivotal follow-up dataset and payer willingness to fund clinic-based, supervised dosing. True commercialization upside plays out over multiple years because access will be constrained by provider capacity, credentialing, and reimbursement, meaning approvals (if obtained) are necessary but not sufficient for rapid revenue realization.

From a strategic perspective, the stock is behaving like a binary clinical-stage asset with an early commercialization overlay — this creates opportunities to isolate event risk (data/FDA alignment) from operational risk (manufacturing, salesforce build). Monitor non-obvious indicators: CMO contractual milestones, specialty clinic partnerships or capacity buildouts, early payer statements about coverage criteria, and any pre-launch contracting with PBMs — each materially moves implied commercialization timelines and valuation multiples.

Contrarian angle: the market is pricing a fast transition to outpatient clinic networks; that is optimistic. If you assume a constrained 2–3 year rollout to reach 5–10% of the addressable TRD population, peak revenue and multiple expansion compress materially versus the “immediate adoption” narrative. That gap between expectation and realistic rollout cadence is where active positioning can harvest asymmetric returns.

Key Decisions for Investors

• Buy CMPS Jan-2028 LEAP calls (25–40% OTM) sized to 1.5–2.0% of portfolio as a long-dated binary play: target 3x if pivotal follow-up and favorable FDA alignment materialize; cut to 30% of initial notional on a 70% loss to limit binary downside.
• Build a core long equity position in CMPS via dollar-cost averaging into post-offering weakness (scale in over 4 tranches across 3 months) sized 1–2% of portfolio; use a 35–45% hard stop per tranche and trim 25–50% into spikes above implied value when major positive regulatory milestones are announced.
• Pair trade to isolate program risk: long CMPS (notional X) / short a basket of speculative psychedelic peers (notional X), rebalanced at each clinical data event — reduces sector beta while keeping directional upside from COMP360’s path to market. Aim for asymmetric payoff where downside is capped by short leg funding relief.
• Sell covered calls against a portion (25–33%) of any core long position with 3–6 month expiries to monetize elevated IV before the next major milestone; accept capping upside in exchange for premium that offsets near-term dilution risk and financing overhang.
• Watchlist triggers (events to add/trim): CMO capacity contracts announced, formal FDA meeting outcomes that expand/limit label, payer pilot agreements, and the pivotal 26-week durability/safety readout window — re-evaluate sizing within 48–72 hours of any such announcement.